Bio-Techne/$TECH
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Bio-Techne
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Ticker
$TECH
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
3,100
ISIN
US09073M1045
Website
Bio-Techne Metrics
BasicAdvanced
$8.3B
64.07
$0.83
1.46
$0.32
0.60%
Price and volume
Market cap
$8.3B
Beta
1.46
52-week high
$83.62
52-week low
$46.01
Average daily volume
2.5M
Dividend rate
$0.32
Financial strength
Current ratio
3.707
Quick ratio
2.233
Long term debt to equity
20.29
Total debt to equity
20.986
Dividend payout ratio (TTM)
38.45%
Interest coverage (TTM)
25.42%
Profitability
EBITDA (TTM)
288.959
Gross margin (TTM)
66.32%
Net profit margin (TTM)
10.89%
Operating margin (TTM)
17.92%
Effective tax rate (TTM)
19.21%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
5.05%
Return on equity (TTM)
6.53%
Valuation
Price to earnings (TTM)
64.073
Price to revenue (TTM)
6.954
Price to book
4.15
Price to tangible book (TTM)
13.82
Price to free cash flow (TTM)
38.075
Free cash flow yield (TTM)
2.63%
Free cash flow per share (TTM)
139.67%
Dividend yield (TTM)
0.60%
Forward dividend yield
0.60%
Growth
Revenue change (TTM)
4.72%
Earnings per share change (TTM)
-34.18%
3-year revenue growth (CAGR)
3.94%
10-year revenue growth (CAGR)
10.98%
3-year earnings per share growth (CAGR)
-15.44%
10-year earnings per share growth (CAGR)
1.29%
10-year dividend per share growth (CAGR)
0.08%
What the Analysts think about Bio-Techne
Analyst ratings (Buy, Hold, Sell) for Bio-Techne stock.
Bulls say / Bears say
Bio-Techne's GMP protein business has experienced significant growth, expanding from less than $5 million to over $60 million in annualized revenue within five years, with a 40% growth rate over the past year. This positions the company favorably in the rapidly growing cell and gene therapy market. (Investing.com)
The company reported a 7% increase in sales within its Protein Sciences unit, reaching $211.6 million in Q2 2025, indicating strong demand for its products used in research, diagnostics, and the development of cell and gene therapies. (TradingView News)
Bio-Techne has announced a new share buyback program of up to $500 million, reflecting confidence in its financial position and commitment to returning value to shareholders. (TradingView News)
Bio-Techne's Q4 2024 organic revenue increased by only 1%, indicating potential challenges in achieving significant growth amidst a competitive market. (Seeking Alpha)
The company missed revenue estimates in Q4 2024, with reported revenue of $306.1 million falling short by $244,370, suggesting potential difficulties in meeting market expectations. (Seeking Alpha)
Citigroup has reduced Bio-Techne's price target to $70.00, reflecting concerns about the company's future growth prospects and market performance. (Techdows News)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
Bio-Techne Financial Performance
Revenues and expenses
Bio-Techne Earnings Performance
Company profitability
Bio-Techne News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bio-Techne stock?
Bio-Techne (TECH) has a market cap of $8.3B as of July 04, 2025.
What is the P/E ratio for Bio-Techne stock?
The price to earnings (P/E) ratio for Bio-Techne (TECH) stock is 64.07 as of July 04, 2025.
Does Bio-Techne stock pay dividends?
Yes, the Bio-Techne (TECH) stock pays dividends to shareholders. As of July 04, 2025, the dividend rate is $0.32 and the yield is 0.6%. Bio-Techne has a payout ratio of 38.45% on a trailing twelve-month basis.
When is the next Bio-Techne dividend payment date?
The next Bio-Techne (TECH) dividend payment date is unconfirmed.
What is the beta indicator for Bio-Techne?
Bio-Techne (TECH) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.